Sarcomas are malignant tumors of mesenchymal origin, which can develop everywhere in the body. Almost all organs can be affected. The bone and soft tissue sarcomas and their respective subtypes sometimes differ drastically in their biological behavior and clinical manifestation. Their treatment can also be varied. There are more thatn 25 different types of bone and over 60 of soft tissue sarcoma. Optimal, individualized treatment requires interdisciplinary care. In addition to the regularly involved disciplines (medical and pediatric oncology, orthopaedic oncology, radiation therapy, visceral surgery), many other disciplines (oral and maxillofacial surgery, otorhinolaryngology, dermatology, and many more) can deal with sarcomas in daily clinical practice.
There are only a few types of sarcomas that have standardized treatment approaches, though differences in the approaches of individual countries are common even then. Moreover, there are different therapy regimens for many entities even within a country.
The clinical care of sarcomas is continuously evolving. New therapy techniques are being transferred from the laboratory bench to daily clinical practice and established in sarcoma treatment protocols. The aim of this research topic is to present the actual developments in quality of life of sarcoma patients, which are continuously being influenced by new therapy developments.
We expect submissions on the following topics for treatment of sarcoma:
- Quality of life after sarcoma treatment
- Interdisciplinary collaboration and treatment development.
The following types of articles are welcome: original articles, clinical trials, clinical reviews, meta-analyses, epidemiologic studies. Case reports could be accepted if they investigate an new approach to treatment.
Please note that manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Sarcomas are malignant tumors of mesenchymal origin, which can develop everywhere in the body. Almost all organs can be affected. The bone and soft tissue sarcomas and their respective subtypes sometimes differ drastically in their biological behavior and clinical manifestation. Their treatment can also be varied. There are more thatn 25 different types of bone and over 60 of soft tissue sarcoma. Optimal, individualized treatment requires interdisciplinary care. In addition to the regularly involved disciplines (medical and pediatric oncology, orthopaedic oncology, radiation therapy, visceral surgery), many other disciplines (oral and maxillofacial surgery, otorhinolaryngology, dermatology, and many more) can deal with sarcomas in daily clinical practice.
There are only a few types of sarcomas that have standardized treatment approaches, though differences in the approaches of individual countries are common even then. Moreover, there are different therapy regimens for many entities even within a country.
The clinical care of sarcomas is continuously evolving. New therapy techniques are being transferred from the laboratory bench to daily clinical practice and established in sarcoma treatment protocols. The aim of this research topic is to present the actual developments in quality of life of sarcoma patients, which are continuously being influenced by new therapy developments.
We expect submissions on the following topics for treatment of sarcoma:
- Quality of life after sarcoma treatment
- Interdisciplinary collaboration and treatment development.
The following types of articles are welcome: original articles, clinical trials, clinical reviews, meta-analyses, epidemiologic studies. Case reports could be accepted if they investigate an new approach to treatment.
Please note that manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
